Celonic Group and Carbogen Amicis: Alliance to deliver fully integrated ADC development and manufacturing platform

This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and CARBOGEN AMCIS aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.

“This strategic alliance is a direct response to the evolving needs of ADC innovators,” said Dr. Samanta Cimitan, CEO of Celonic Group. “By integrating Celonic’s advanced biologics platforms with CARBOGEN AMCIS’s world-class payload and conjugation capabilities, we’re enabling a fully harmonised development and manufacturing pathway, from DNA to drug product. It’s a scalable, compliant, and commercially ready solution designed to accelerate innovation and reduce complexity for our partners.”

Investing where it matters:

• Celonic Group recently expanded its Biologics Development Center in Basel and GMP manufacturing site in Heidelberg, adding high-yield GS-CHOvolution cell line platform, enhanced perfusion-based technologies for process optimization to improve productivity, and commercial-scale biomanufacturing suites.

• CARBOGEN AMCIS delivered its first ADC project in 2005 and has since supported numerous ADC programs across payload, linker, conjugation, and sterile drug product – giving innovators a single accountable partner from early development through market supply. As one of the earliest CDMOs to build dedicated ADC capabilities, CARBOGEN AMCIS has become a go‑to partner for linker and payload development and for conjugation with customer‑supplied antibodies. The dedicated conjugation suites in Switzerland and clinical‑to‑commercial and commercial manufacturing of sterile liquid drug‑product capability at an ANMS approved, state of the art green field facility in France provide end to end development at supply across all clinical phases and extensive commercial volume range, with high precision, speed, quality and reliability demanded, across all the programs.

“The new targeted cancer treatments have fueled a rising demand for ADCs, and this alliance positions us to meet that demand with unmatched technical expertise and operational agility,” said Stephan Fritschi, CEO of Carbogen Amcis Group. “Together, we offer a comprehensive service for ADC development, streamlined, scalable, and globally compliant.”

“For more than 2 decades now we’ve been the preferred partner for linker & payload development and until now, with customer supplied monoclonal antibodies, precise conjugation. We are excited that henceforth, through our partnership with Celonic, innovators will now get a seamless, end‑to‑end ADC path—from cell line to commercial fill‑finish—under one coordinated platform,” adds Arpit Vyas, Global Managing Director of Dishman and Carbogen Amcis Group. “Beyond linker and payload excellence, we are deeply evaluating a cutting edge innovative capacity expansion intending continuous‑flow conjugation using custom micro‑equipment skids. By holding pH, temperature, stoichiometry, and residence time within tight bands.

The integrated offering includes:

• Cell line development and antibody production at scale (Celonic)
• Payload and linker synthesis and at scale manufacturing (CARBOGEN AMCIS)
• ADC conjugation and sterile fill-finish (CARBOGEN AMCIS)
• Regulatory support and CMC documentation for IND, IMPD, and BLA filings

With Celonic upstream and CARBOGEN AMCIS downstream, teams get one accountable partner. This alliance removes variability and removes handoffs so that such life-saving therapies reach families sooner, across the globe.